Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Imugene Reports 86% Response Rate in Azer-Cel Combination Trial as Cash Outflow Falls

Imugene Limited (IMU) · Health care

IMU: $0.035 -7.89% · MC: $20M

Imugene reported responses in six of seven evaluable patients in its azer-cel BTKi combination cohort, an 86% response rate, while the CAR T-naïve cohort recorded an 81% response rate after quarter end. Quarterly net operating cash outflow fell 19% from the prior quarter, with staff costs down 51%; cash stood at approximately $5 million before an expected R&D tax incentive refund. The results are early and based on small patient groups, with further follow-up needed to assess response durability.

Source announcements: 2026-10-30 09:43 to 2026-10-30 09:43 Sydney time
Story updated 2026-10-30 09:46 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments